Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 43.62 Million EUR | -43.04% |
| 2022 | 76.59 Million EUR | -26.91% |
| 2021 | 104.79 Million EUR | 638.52% |
| 2020 | 14.19 Million EUR | -39.22% |
| 2019 | 23.34 Million EUR | 144.19% |
| 2018 | 9.56 Million EUR | 16.83% |
| 2017 | 8.18 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 46.85 Million EUR | 0.0% |
| 2024 Q1 | 46.85 Million EUR | 7.39% |
| 2023 Q4 | 43.62 Million EUR | 0.0% |
| 2023 Q1 | 59.02 Million EUR | -22.93% |
| 2023 FY | 43.62 Million EUR | -43.04% |
| 2023 Q3 | 43.62 Million EUR | -26.09% |
| 2023 Q2 | 59.02 Million EUR | 0.0% |
| 2022 Q3 | 76.59 Million EUR | -17.15% |
| 2022 Q2 | 92.45 Million EUR | 0.0% |
| 2022 Q4 | 76.59 Million EUR | 0.0% |
| 2022 Q1 | 92.45 Million EUR | -11.78% |
| 2022 FY | 76.59 Million EUR | -26.91% |
| 2021 Q4 | 104.79 Million EUR | 0.0% |
| 2021 FY | 104.79 Million EUR | 638.52% |
| 2021 Q3 | 104.79 Million EUR | 211.39% |
| 2021 Q2 | 33.65 Million EUR | 0.0% |
| 2021 Q1 | 33.65 Million EUR | 137.17% |
| 2020 Q4 | 14.19 Million EUR | 0.0% |
| 2020 Q3 | 14.19 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 14.19 Million EUR | -39.22% |
| 2019 FY | 23.34 Million EUR | 144.19% |
| 2018 FY | 9.56 Million EUR | 16.83% |
| 2017 FY | 8.18 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -196.594% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 86.66% |
| Adocia SA | 24.95 Million EUR | -74.824% |
| Aelis Farma SA | 26.28 Million EUR | -66.01% |
| Biophytis S.A. | 11.93 Million EUR | -265.524% |
| Advicenne S.A. | 12.4 Million EUR | -251.648% |
| genOway Société anonyme | 31.84 Million EUR | -37.016% |
| IntegraGen SA | 8 Million EUR | -445.339% |
| Medesis Pharma S.A. | 1.92 Million EUR | -2164.871% |
| Neovacs S.A. | 47.53 Million EUR | 8.214% |
| NFL Biosciences SA | 3.97 Million EUR | -998.793% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -192.558% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -1064.443% |
| Sensorion SA | 46.49 Million EUR | 6.162% |
| Theranexus Société Anonyme | 7.23 Million EUR | -502.799% |
| TME Pharma N.V. | 2.49 Million EUR | -1651.465% |
| Valbiotis SA | 33.24 Million EUR | -31.223% |
| TheraVet SA | 7.53 Million EUR | -479.08% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -23.686% |
| argenx SE | 4.11 Billion EUR | 98.939% |
| BioSenic S.A. | 9.55 Million EUR | -356.418% |
| Celyad Oncology SA | 16.28 Million EUR | -167.958% |
| DBV Technologies S.A. | 165.65 Million USD | 73.662% |
| Galapagos NV | 4.35 Billion EUR | 98.999% |
| Genfit S.A. | 173.87 Million EUR | 74.907% |
| GeNeuro SA | 6.31 Million EUR | -591.109% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 8.498% |
| Innate Pharma S.A. | 184.19 Million EUR | 76.313% |
| Inventiva S.A. | 69.13 Million EUR | 36.897% |
| MaaT Pharma SA | 42.93 Million EUR | -1.626% |
| MedinCell S.A. | 36.94 Million EUR | -18.082% |
| Nanobiotix S.A. | 93.89 Million EUR | 53.535% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 59.187% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 46.729% |
| Oxurion NV | 6.55 Million EUR | -566.092% |
| Pharming Group N.V. | 426.33 Million EUR | 89.767% |
| Poxel S.A. | 4.82 Million EUR | -804.603% |
| GenSight Biologics S.A. | 9.08 Million EUR | -380.125% |
| Transgene SA | 45.21 Million EUR | 3.512% |
| Financière de Tubize SA | 1.92 Billion EUR | 97.728% |
| UCB SA | 15.53 Billion EUR | 99.719% |
| Valneva SE | 469.39 Million EUR | 90.705% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -41.519% |